TrialSignal transduction and targeted therapy2025

Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial.

Huijie Bian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.